Skip to content
DataLookout
Menu

ATMOSNCT07720375

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 4 → 7 locations
  2. Notable Eligibility criteria expanded, about 26 words
    • Study sites: 4 to 6
    • Secondary endpoints: details revised at 5 of 5 entries
  3. Notable Eligibility criteria revised
    • Study sites: 3 to 4
    v4
  4. Notable Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Jul 31, 2026 to Aug 5, 2026
    v3
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time from intervention assignment to first moderate or severe pulmonary exacerbation
Timeframe: Up to Week 52

Secondary (5)

Annualized rate of pulmonary exacerbations
Post bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at Week 24
Incidence of Treatment-Emergent (TE) Adverse Events (AE)
Incidence of TE Serious Adverse Events (SAEs)
Change from Baseline in Quality of life questionnaire-bronchiectasis (QOL-B) Respiratory Symptoms Domain Scores at Week 24

Arms and interventions

Galvokimig Dose 1 ArmExperimental

Participants randomly assigned to this arm will receive Galvokimig Dose 1

Galvokimig Dose 2 ArmExperimental

Participants randomly assigned to this arm will receive Galvokimig Dose 2

Galvokimig Dose 3 ArmExperimental

Participants randomly assigned to this arm will receive Galvokimig Dose 3

Placebo ArmPlacebo comparator

Participants randomly assigned to this arm will receive a matching Placebo.

Biologicals: Galvokimig, Placebo

Sites

7 sites in 1 country